Drug profile · INN
fulvestrant
FULVESTRANT ACCORD
fulvestrant (FULVESTRANT ACCORD) is a estrogen receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — fulvestrant
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L02)
- Route
- INTRAMUSCULAR
- Patents
- 7
- Programs
- 47
- Data quality
- 0.89
Quick answer
fulvestrant (FULVESTRANT ACCORD) is a estrogen receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Estrogen receptor antagonist
Primary target: Estrogen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12281056
Methods for making and using endoxifen
granted -
US 12275684
Methods for making and using endoxifen
granted -
US 12201591
Sustained release compositions of endoxifen
granted -
US 12071391
Methods for making and using endoxifen
granted -
US 11680036
Methods for making and using endoxifen
granted -
US 11572334
Methods for making and using endoxifen
granted -
US 11261151
Methods for making and using endoxifen
granted
Frequently asked questions
What is fulvestrant?
fulvestrant (FULVESTRANT ACCORD) is a estrogen receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for fulvestrant?
FULVESTRANT ACCORD is a marketed brand name for fulvestrant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fulvestrant?
fulvestrant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.